- Home
- HUHU vs LPTX Comparison
HUHU vs LPTX Comparison
Compare HUHU & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- LPTX
- Stock Information
- Founded
- HUHU 2015
- LPTX 2011
- Country
- HUHU China
- LPTX United States
- Employees
- HUHU N/A
- LPTX N/A
- Industry
- HUHU
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUHU
- LPTX Health Care
- Exchange
- HUHU NYSE
- LPTX Nasdaq
- Market Cap
- HUHU 106.3M
- LPTX 119.6M
- IPO Year
- HUHU 2024
- LPTX N/A
- Fundamental
- Price
- HUHU $4.93
- LPTX $0.41
- Analyst Decision
- HUHU
- LPTX Buy
- Analyst Count
- HUHU 0
- LPTX 2
- Target Price
- HUHU N/A
- LPTX $8.00
- AVG Volume (30 Days)
- HUHU 12.3K
- LPTX 330.3K
- Earning Date
- HUHU 02-22-2025
- LPTX 08-11-2025
- Dividend Yield
- HUHU N/A
- LPTX N/A
- EPS Growth
- HUHU N/A
- LPTX N/A
- EPS
- HUHU N/A
- LPTX N/A
- Revenue
- HUHU $18,149,244.00
- LPTX N/A
- Revenue This Year
- HUHU N/A
- LPTX N/A
- Revenue Next Year
- HUHU N/A
- LPTX N/A
- P/E Ratio
- HUHU N/A
- LPTX N/A
- Revenue Growth
- HUHU 8.47
- LPTX N/A
- 52 Week Low
- HUHU $2.95
- LPTX $0.22
- 52 Week High
- HUHU $9.89
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- LPTX 53.79
- Support Level
- HUHU N/A
- LPTX $0.40
- Resistance Level
- HUHU N/A
- LPTX $0.46
- Average True Range (ATR)
- HUHU 0.00
- LPTX 0.04
- MACD
- HUHU 0.00
- LPTX 0.00
- Stochastic Oscillator
- HUHU 0.00
- LPTX 52.16
About HUHU HUHUTECH INTL GROUP INC
HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .